FY2026 EPS Forecast for Scholar Rock Increased by Analyst

Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) - Equities research analysts at HC Wainwright upped their FY2026 earnings estimates for Scholar Rock in a report issued on Tuesday, November 26th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($1.57) for the year, up from their previous estimate of ($1.68). HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.40) per share. HC Wainwright also issued estimates for Scholar Rock's FY2027 earnings at ($0.78) EPS and FY2028 earnings at $0.18 EPS.

Other analysts have also issued reports about the company. Piper Sandler raised their target price on Scholar Rock from $28.00 to $42.00 and gave the company an "overweight" rating in a research note on Tuesday, October 15th. JPMorgan Chase & Co. boosted their target price on shares of Scholar Rock from $18.00 to $31.00 and gave the stock an "overweight" rating in a research note on Monday, October 14th. BMO Capital Markets increased their price target on shares of Scholar Rock from $34.00 to $38.00 and gave the company an "outperform" rating in a research note on Friday, October 11th. Truist Financial boosted their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Wedbush increased their price objective on Scholar Rock from $40.00 to $47.00 and gave the company an "outperform" rating in a research report on Monday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $40.43.

Scholar Rock Price Performance

SRRK traded up $1.09 during trading on Thursday, hitting $38.15. The company's stock had a trading volume of 757,923 shares, compared to its average volume of 1,152,049. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $3.57 billion, a price-to-earnings ratio of -16.23 and a beta of 0.47. The firm's 50 day moving average price is $24.29 and its two-hundred day moving average price is $14.54. Scholar Rock has a 12 month low of $6.76 and a 12 month high of $43.38.

Hedge Funds Weigh In On Scholar Rock

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Scholar Rock by 4.0% during the first quarter. Vanguard Group Inc. now owns 2,969,534 shares of the company's stock worth $52,739,000 after acquiring an additional 114,550 shares in the last quarter. American International Group Inc. grew its position in shares of Scholar Rock by 3.0% in the 1st quarter. American International Group Inc. now owns 28,407 shares of the company's stock valued at $505,000 after purchasing an additional 834 shares during the period. Bayesian Capital Management LP bought a new stake in Scholar Rock during the 1st quarter worth approximately $258,000. Jane Street Group LLC raised its holdings in Scholar Rock by 95.5% during the 1st quarter. Jane Street Group LLC now owns 244,318 shares of the company's stock worth $4,339,000 after buying an additional 119,363 shares during the period. Finally, Walleye Trading LLC bought a new position in Scholar Rock in the first quarter valued at approximately $178,000. Institutional investors and hedge funds own 91.08% of the company's stock.

Insiders Place Their Bets

In related news, Director Srinivas Akkaraju sold 1,175,713 shares of Scholar Rock stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $29.25, for a total transaction of $34,389,605.25. Following the transaction, the director now owns 5,612,896 shares of the company's stock, valued at $164,177,208. This trade represents a 17.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Public Equities L.P. Invus sold 409,433 shares of the company's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the completion of the sale, the insider now directly owns 10,850,005 shares of the company's stock, valued at $417,616,692.45. The trade was a 3.64 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,823,322 shares of company stock valued at $56,411,627. Company insiders own 19.20% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.